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The American Diabetes Association and the European Association for the Study of
Diabetes have briefly updated their 2018 recommendations on management of
hyperglycemia, based on important research findings from large cardiovascular
outcomes trials published in 2019. Important changes include: 1) the decision to
treat high-risk individuals with a glucagon-like peptide 1 (GLP-1) receptor agonist or
sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse car-
diovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular
death, or chronic kidney disease (CKD) progression should be considered
independently of baseline HbA1c or individualized HbA1c target; 2) GLP-1 receptor
agonists can also be considered in patientswith type 2diabeteswithout established
cardiovascular disease (CVD)butwith thepresenceof specific indicators of high risk;
and3) SGLT2 inhibitors are recommended inpatientswith type2diabetes andheart
failure, particularly those with heart failure with reduced ejection fraction, to
reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with
CKD (estimated glomerular filtration rate 30 to £60 mL min–1 [1.73 m]–2 or urinary
albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the
progression of CKD, hHF, MACE, and cardiovascular death.
The American Diabetes Association (ADA) and the European Association for the Study of
Diabetes (EASD) requestedabrief updateof the2018 recommendationsonmanagement
of hyperglycemia (1,2), based on the important research findings published in 2019, with
a particular focus on new data from large cardiovascular outcomes trials (CVOTs). The
authors began work on the brief update in July 2019 and submitted it for publication in
Diabetes Care and Diabetologia in October 2019. Work was conducted over a series of
phone calls and by electronic interactions. This brief update provides a summary of the
implications of this new evidence on recommendations for the management of
hyperglycemia in type 2 diabetes (see text box), whichwill be addressedmore fully in the
ADA Standards of Medical Care in Diabetesd2020 (https://professional.diabetes.org/
SOC). It should be considered in conjunction with the 2018 consensus report (1,2).
The Researching Cardiovascular Events with a Weekly Incretin in Diabetes
(REWIND) trial of the glucagon-like peptide 1 (GLP-1) receptor agonist dulaglutide
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included a greater proportion of individ-
uals with type 2 diabetes with high car-
diovascular riskbutwithoutpriorestablished
cardiovascular disease (CVD) (68.5%) and
with longer follow-up (median 5.4 years)
than prior CVOTs (3). The primary major
adverse cardiovascular event (MACE) out-
comeoccurred in2.7 per 100patient-years
with a hazard ratio (HR) of 0.88 (95% CI
0.79, 0.99) in favor of dulaglutide. There
wasnodifference in theMACEeffect in the
subpopulations with and without a history
of CVD, although the treatment effect of
dulaglutide did not reach statistical signif-
icance when the groups were considered
separately. Most other CVOTs with GLP-1
receptor agonists have included aminority
of patients with risk factors only but with-
out evidence of benefit onMACE outcomes
in the lower-risk subgroups. Whether the
differences in outcomes in trial subgroups
without established CVD are related to
study details or to the assigned therapy is
uncertain. In REWIND, prior CVD was de-
fined as a history of myocardial infarction,
ischemic stroke, unstable anginawith elec-
trocardiogram (ECG) changes, myocardial
ischemia on imaging or stress test, or
coronary, carotid, or peripheral revascu-
larization. We previously recommended
that established CVD was a compelling
indication for treatment with a GLP-1
receptor agonist or sodium–glucose co-
transporter 2 (SGLT2) inhibitor. We now
also suggest that to reduce risk ofMACE,
GLP-1 receptor agonists can also be con-
sidered in patients with type 2 diabetes
without established CVD with indicators
of high risk, specifically, patients aged
55 years or olderwith coronary, carotid,
or lower extremity artery stenosis >50%,
left ventricular hypertrophy, an estimated
glomerularfiltration rate (eGFR)<60mL
min–1 [1.73m]–2, or albuminuria. To date,
the levelofevidence tosupport theuseof
GLP-1 receptor agonists for primary pre-
vention is strongest for dulaglutide but
lacking forotherGLP-1 receptor agonists.
The Dapagliflozin Effect on Cardiovas-
cular Events–Thrombolysis inMyocardial
Infarction 58 (DECLARE–TIMI 58) trial
compared the SGLT2 inhibitor dapagli-
flozin with placebo and also enrolled a
greater proportion of participants with
type 2 diabeteswithout prior established
CVDbutwithmultiple risk factors (59.4%)
and with longer follow-up (median 4.2
years) than other SGLT2 inhibitor trials
(4). Dapagliflozin demonstrated cardio-
vascular (CV) safety but not a benefit for
the MACE end point (HR 0.93; 95% CI
0.84, 1.03). Dapagliflozin was associated
with benefit for the coprimary efficacy
end point of CV death or hospitalization
for heart failure (hHF) with HR 0.83 (95%
CI 0.73, 0.95) as well as renal end points.
For MACE, the HR in the multiple risk
factor group without established athero-
sclerotic vascular disease was 1.01, but
this group had strong evidence for ben-
efit for the composite of CVdeath or hHF.
Meta-analysis of the SGLT2 inhibitor
CVOTs suggests a class effect to reduce
hHF and chronic kidney disease (CKD)
progression across high and lower CVD
risk subgroups with no effect on MACE
in the absence of established athero-
sclerotic vascular disease (5).
Analysis of two SGLT2 inhibitor CVOTs,
DECLARE–TIMI 58 (6) and the Canagli-
flozin Cardiovascular Assessment Study
(CANVAS) Program (7), suggests that the
benefits of SGLT2 inhibitors for hHF,
MACE, and CV death are greatest for
those individuals with preexisting heart
failure with reduced ejection fraction
(HFrEF) compared with those without
HFrEF. It is important to note that hHF
was a secondary outcome, relatively low
numbers of patients had HF at baseline,
and data on ejection fraction (EF) were
only available for a proportion of pa-
tients. In DECLARE–TIMI 58, individuals
with HF but no reduction of EF as well as
thosewithout HF did not seem to benefit
from dapagliflozin treatment to lower
MACE and CV death outcomes. The ben-
efit for hHF was strongest for those who
at baseline had an EF ,30%, strong for
those with an EF,45%, andmarginal for
those with an EF$45% or those without
HF. The Dapagliflozin and Prevention of
Adverse Outcomes in Heart Failure (DAPA-
HF) trial of dapagliflozin was the first heart
failure outcome trial of a diabetes med-
ication (8). Recruitment included pa-
tients with and without type 2 diabetes
with heart failure and an EF #40% and
demonstrated benefits for reduction of
the primary composite end point of CV
death, hHF, and urgent HF visits, as well
as for HF events and mortality (CV and
total) considered separately. We now
suggest that SGLT2 inhibitors are recom-
mended in patients with type 2 diabetes
and HF, particularly those with HFrEF, to
reduce hHF, MACE, and CV death.
Changes to consensus recommendations
We previously recommended that, in the setting of type 2 diabetes, established CVD was a compelling indication for treatment with a GLP-1
receptor agonist or SGLT2 inhibitor. We now further suggest the following:
General consideration
c In appropriate high-risk individuals with established type 2 diabetes, the decision to treat with a GLP-1 receptor agonist or SGLT2 inhibitor to
reduce MACE, hHF, CV death, or CKD progression should be considered independently of baseline HbA1c or individualized HbA1c target.
c Providers should engage in shared decision making around initial combination therapy in new-onset cases of type 2 diabetes.
GLP-1 receptor agonist recommendations
c For patients with type 2 diabetes and established atherosclerotic CV disease (such as those with prior myocardial infarction, ischemic stroke,
unstable anginawith ECG changes,myocardial ischemia on imaging or stress test, or revascularization of coronary, carotid, or peripheral arteries)
where MACE is the gravest threat, the level of evidence for MACE benefit is greatest for GLP-1 receptor agonists.
c To reduce riskofMACE,GLP-1 receptor agonists canalsobe considered inpatientswith type2diabeteswithoutestablishedCVDwith indicatorsof
high risk, specifically, patientsaged55yearsorolderwith coronary, carotid,or lowerextremity artery stenosis.50%, left ventricularhypertrophy,
eGFR ,60 mL min–1 [1.73 m]–2, or albuminuria.
SGLT2 inhibitor recommendations
c For patients with or without established atherosclerotic CVD, but with HFrEF (EF ,45%) or CKD (eGFR 30 to #60 mL min–1 [1.73 m]–2 or
UACR .30 mg/g, particularly UACR .300 mg/g), the level of evidence for benefit is greatest for SGLT2 inhibitors.
c SGLT2 inhibitors are recommended in patients with type 2 diabetes and HF, particularly those with HFrEF, to reduce hHF, MACE, and CV death.
c SGLT2 inhibitors are recommended to prevent the progression of CKD, hHF, MACE, and CV death in patients with type 2 diabetes with CKD.
c Patients with foot ulcers or at high risk for amputation should only be treated with SGLT2 inhibitors after careful shared decisionmaking around












































































































































Figure 2—Choosing glucose-lowering medication in those with indicators of high-risk or established atherosclerotic cardiovascular disease (ASCVD),
chronic kidney disease (CKD), or heart failure (HF). RA, receptor agonist; SU, sulfonylureas; TZD, thiazolidinediones. Adapted from Davies et al. (1).
© American Diabetes Association and European Association for the Study of Diabetes, 2018.
The REWIND trial of the GLP-1 recep-
tor agonist dulaglutide had no lower limit
to HbA1c for eligibility and demonstrated
equivalent efficacy for reduction of MACE
above and below the median HbA1c of
55 mmol/mol (7.2%) (3). None of the
CVOTs of SGLT2 inhibitors with primary
MACE end points have recruited patients
with an HbA1c ,48 mmol/mol (,6.5%),
and there is little data to inform clinical
decision making for patients with an
HbA1c ,53 mmol/mol (,7%) (9). How-
ever, the outcome benefits observed in
the CVOTs do not appear restricted to
patients with an elevated HbA1c. That
said, the DAPA-HF trial recruited patients
withHFrEFwith andwithoutdiabetes (8).
The benefit for reduction of mortality
rate andHF eventswith dapagliflozinwas
significant in both subgroups, suggesting
that the effects of dapagliflozin on these
end points is independent of HbA1c (8).
Wenow recommend that in appropriate
high-risk individuals with established
type 2 diabetes, the decision to treat
with a GLP-1 receptor agonist or SGLT2
inhibitor to reduce MACE, hHF, cardio-
vascular death, or CKD progression
should be considered independently of
baseline HbA1c or individualized HbA1c
target. That said, there are no specific
analyses addressing HbA1c ,48 mmol/
mol (,6.5%). We continue to recom-
mend that substituting a drug with
knownCVD, CKD, andhHFbenefit for one
without known benefit in high-risk pa-
tients is reasonable when patients are at
individualized glycemic targets.
The Canagliflozin and Renal Events in
Diabetes with Established Nephropathy
Clinical Evaluation (CREDENCE) trial of
the SGLT2 inhibitor canagliflozin was the
first renal outcome trial of a diabetes
medication (10) with a primary compos-
ite end point of end-stage kidney disease
(dialysis, transplantation, or a sustained
eGFR of ,15 mL min–1 [1.73 m]–2), a
doubling of the serum creatinine level, or
death from renal or cardiovascular causes.
The trial recruited patients with type 2
diabetes and CKD on the maximally tol-
erated dose of ACE inhibitors or angio-
tensin receptor blockers with a urinary
albumin-to-creatinine ratio (UACR) of
300–5,000 mg/g and an eGFR of 30
to ,90 mL min–1 [1.73 m]–2. This trial
demonstrated a clear benefit of canagli-
flozin (100 mg) on multiple renal end
points, including progression to end-
stage kidney disease, and on cardiovascular
mortality, MACE, and hHF. Furthermore,
the CREDENCE results demonstrated that
the benefits conferred by canagliflozin in
terms of reducing MACE, hHF, cardio-
vascular mortality, and renal end points
were similar regardless of baseline status
for cardiovascular or CKD grade 2–3 (11).
We now recommend that SGLT2 inhib-
itors should be used to prevent hHF,
MACE, and CV death and the progres-
sion of CKD in patients with type 2
diabeteswithCKD. The benefits are clear-
cut for those with UACR.300 mg/g and
eGFR 30–90 mL min–1 [1.73 m]–2 and less
well established for lesser grades of CKD
based on secondary end point analyses of
the CVOT.
A concern in the CANVAS Programwas
the increased risk of amputation with
canagliflozin compared with placebo (7).
In CREDENCE (10), although the risk of
amputation was higher overall than in
other SGLT2 inhibitor trials, no significant
increase in risk was observed with can-
agliflozin 100 mg versus placebo (HR
1.11; 95% CI 0.79, 1.56). This may be
due to the risk mitigation strategies
employed: exclusion of patients with a
history of a traumatic amputation within
12months of screening, or an active foot
ulcer, osteomyelitis, gangrene, or critical
ischemia of the lower extremity within
6 months of screening; and interruption
of therapy for emergence of any of the
above with careful consideration of the
individual risks and benefits prior to
restarting canagliflozin after resolution
of the event. We now recommend that
patients with foot ulcers or at high risk
for amputation should only be treated
with SGLT2 inhibitors after careful
shared decision making around risks
and benefits with comprehensive ed-
ucation on foot care and amputation
prevention.
Based on the studies published thus
far, we believe that for patients with
type 2 diabetes and established athero-
sclerotic CVD (such as those with prior
myocardial infarction, ischemic stroke,
unstable anginawith ECGchanges,myo-
cardial ischemia on imaging or stress
test, or revascularization of coronary,
carotid, or peripheral arteries) where
MACE is thegravest threat, that the level
of evidence forMACE benefit is greatest
for GLP-1 receptor agonists.
The Peptide Innovation for Early Di-
abetes Treatment 6 (PIONEER 6) cardio-
vascular safety trial of oral semaglutide, a
GLP-1 receptor agonist, involved 3,183
patients with type 2 diabetes followed
for only a median of 16 months, but it
provided adequate demonstration of
cardiovascular safety (HR 0.79; 95% CI
0.57, 1.11) and a strong signal for re-
duction of CV mortality rate (HR 0.49;
95% CI 0.27, 0.92) (12). This formulation
of semaglutide has been approved for
marketing in theU.S. andadecision in the
European Union is expected soon.
For patients with or without estab-
lished atherosclerotic CVD, but with
HFrEF or CKD (eGFR 30 to £60 mL min–1
[1.73 m]–2 or UACR >30 mg/g, partic-
ularly UACR >300 mg/g), the level of
evidence for benefit is greatest for SGLT2
inhibitors. For patients with type 2 di-
abetes at low cardiovascular risk and
without CKD, there have been no studies
to examine the cardiovascular or renal
benefit of GLP-1 receptor agonists or
SGLT2 inhibitors.
Somemeta-analyses (5,13,14) suggest
the presence of heterogeneity in esti-
mates forMACE andCVdeathwithGLP-1
receptor agonists, although this ismostly
due to the results of a single trial with
lixisenatide. Likewise, there is some het-
erogeneity in the estimate for CV death
with SGLT2 inhibitors. Whether differ-
ences in point estimates of benefits and
harms are the result of differences in the
effects of the medications, the design
and conduct of the trials, or chance
effects is uncertain. Attention to pa-
tient-specific factors and preferences,
product labeling, meta-analyses, and
the primary research reports should drive
individualized clinical decisionmakingwith
regard to prescribing particular medica-
tions within a class. For many patients,
treatment with a GLP-1 receptor agonist
or SGLT2 inhibitor in some health care set-
tings involves considerable direct cost to
them, and the impact of this on their overall
well-being needs to be factored into de-
cision making.
The Cardiovascular Outcome Study of
Linagliptin Versus Glimepiride in Type 2
Diabetes (CAROLINA) trial randomized
adults at high cardiovascular risk to re-
ceive the dipeptidyl peptidase 4 (DPP-4)
inhibitor linagliptin or to receive the sulfo-
nylurea glimepiride to evaluate a primary
MACE end point. No between-group dif-
ference in the primary end point was
demonstrated (HR 0.98; 95% CI 0.84,
1.14). At trial end, for linagliptin as com-
pared with glimepiride, there was a 1.5-kg
weight loss benefit, no difference in HbA1c
or introductionof glucose-loweringmed-
ications postbaseline, and substantial
benefits in terms of reductions in hy-
poglycemia, though serious hypoglyce-
mic events were rare with glimepiride
(0.45/100 patient-years) (15). Paired
with other DPP-4 inhibitor CVOTs, includ-
ing Cardiovascular and Renal Microvas-
cular Outcome Study with Linagliptin
(CARMELINA) (16), which demonstrated
the CV safety of linagliptin, this is a
reassuring safety signal for glimepiride,
an inexpensive and effective sulfonylurea.
It is unclear whether these findings extend
to other sulfonylureas.
Whereas we previously stated that there
was limited evidence for initial combina-
tion therapy, the Vildagliptin Efficacy in
Combination with Metformin for Early
Treatment of Type 2 Diabetes (VERIFY)
trial provides additional information. The
initial combination of the DPP-4 inhibitor
vildagliptin andmetformin was shown to
provide for a lower rate of secondary
failure of glycemic control to HbA1c $53
mmol/mol ($7%) versus metformin alone
or the sequential addition of metformin
and vildagliptin (17). We now suggest
that providers should engage in shared
decision making around initial combina-
tion therapy in new-onset cases of type 2
diabetes.
There are several major questions re-
garding the optimal application of new
diabetes drugs. One obvious question aris-
ing from recent trial results is whether
combined use of GLP-1 receptor agonists
and SGLT2 inhibitors provides additional
benefit for the prevention of MACE, CV
death, hHF, and CKD progression. Three
trials have demonstrated the HbA1c-low-
ering and weight-reduction efficacy of
the combination (18–20), but none ad-
dresses the impact of the combination of
the two on cardiorenal end points.
A second question that arises from the
recent secondary analyses of SGLT2
inhibitor studies is whether there are
subsets of patients who benefit dispro-
portionately, or very little, from treat-
mentwith the newer diabetes drugs. The
emerging evidence that SGLT2 inhibitors
may be particularly useful in preventing
adverse outcomes in patients with di-
abeteswithHFrEF raises the possibility of
more targeted use of these agents. Fi-
nally, the mechanism(s) of action by
whichGLP-1 receptor agonists and SGLT2
inhibitors confer cardiorenal benefit in
diabetes are not understood. Research
in this area will be very useful in opti-
mizing the now clear potential of drugs
for diabetes to mitigate the cardiovas-
cular and renal complications of the
disease.
Modifications to the main figures of
the prior publication are suggested as
shown in Figs. 1 and 2.
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